Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
1.690
-0.070 (-3.98%)
Jul 29, 2026, 2:05 PM EDT - Market open
BDTX Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 30.07 | 20.99 | 36.44 | 56.22 | 34.32 | 65.8 |
Short-Term Investments | 88.19 | 107.66 | 62.14 | 75.18 | 88.49 | 143.99 |
Cash & Short-Term Investments | 118.26 | 128.65 | 98.58 | 131.4 | 122.81 | 209.79 |
Cash Growth | -22.40% | 30.51% | -24.98% | 7.00% | -41.46% | -33.41% |
Other Current Assets | 4.71 | 3.79 | 2.6 | 2.63 | 4.9 | 5.92 |
Total Current Assets | 122.97 | 132.44 | 101.18 | 134.03 | 127.71 | 215.7 |
Net Property, Plant & Equipment | 9.1 | 9.67 | 20.4 | 23.71 | 27.38 | 30.74 |
Other Long-Term Assets | 0.86 | 0.9 | 1.07 | 0.82 | 1.17 | 1.24 |
Total Assets | 132.92 | 143.01 | 122.64 | 158.57 | 156.26 | 247.68 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.97 | 0.58 | 4.01 | 2.32 | 1.88 | 4.11 |
Accrued Expenses | 11.57 | 15.15 | 16.57 | 17.32 | 13.38 | 19.54 |
Total Current Liabilities | 14.53 | 15.73 | 20.57 | 19.65 | 15.26 | 23.64 |
Long-Term Leases | 14.09 | 15.07 | 18.78 | 22.19 | 25.3 | 28.14 |
Total Long-Term Liabilities | 14.09 | 15.07 | 18.78 | 22.19 | 25.3 | 28.14 |
Total Liabilities | 28.62 | 30.8 | 39.36 | 41.83 | 40.56 | 51.78 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 578.1 | 576.84 | 570.36 | 534.19 | 452.5 | 440.13 |
Accumulated Other Comprehensive Income | -0.04 | 0.1 | 0.02 | -0.03 | -1.82 | -0.41 |
Retained Earnings | -473.78 | -464.74 | -487.11 | -417.43 | -334.99 | -243.82 |
Shareholders' Equity | 104.3 | 112.21 | 83.29 | 116.74 | 115.7 | 195.9 |
Total Liabilities & Equity | 132.92 | 143.01 | 122.64 | 158.57 | 156.26 | 247.68 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 14.09 | 15.07 | 18.78 | 22.19 | 25.3 | 28.14 |
Net Cash (Debt) | 104.17 | 113.58 | 79.79 | 109.22 | 97.51 | 181.65 |
Net Cash Growth | -22.56% | 42.35% | -26.94% | 12.01% | -46.32% | -40.90% |
Net Cash Per Share | 1.83 | 1.97 | 1.45 | 2.48 | 2.68 | 5.02 |
Book Value | 104.3 | 112.21 | 83.29 | 116.74 | 115.7 | 195.9 |
Book Value Per Share | 1.83 | 1.95 | 1.51 | 2.66 | 3.18 | 5.41 |
Tangible Book Value | 104.3 | 112.21 | 83.29 | 116.74 | 115.7 | 195.9 |
Tangible Book Value Per Share | 1.83 | 1.95 | 1.51 | 2.66 | 3.18 | 5.41 |